<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03698279</url>
  </required_header>
  <id_info>
    <org_study_id>QHD04</org_study_id>
    <secondary_id>U1111-1189-3713</secondary_id>
    <secondary_id>2018-005026-39</secondary_id>
    <nct_id>NCT03698279</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age</brief_title>
  <acronym>QHD04</acronym>
  <official_title>Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study were:

        -  To describe the safety of each dosage of high-dose quadrivalent influenza vaccine
           (QIV-HD) used in the study during the 28 days following each vaccination, and serious
           adverse events (including adverse events of special interest throughout the study).

        -  To describe the antibody response induced by each dosage of QIV-HD used in the study
           compared with unadjuvanted standard-dose quadrivalent influenza vaccine (QIV-SD) by
           hemagglutination inhibition (HAI) measurement method.

        -  To describe the antibody response induced by each dosage of QIV-HD used in the study
           compared with unadjuvanted QIV-SD by virus seroneutralization (SN) measurement method.

        -  To describe the antibody response induced by the highest acceptable dosage of QIV-HD
           compared with adjuvanted trivalent influenza vaccine (TIV) by HAI and virus SN
           measurement methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participant was approximately 180 days for participants who received one
      dose of vaccine and 208 days for participants who received two doses of vaccine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 9, 2018</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study was divided into 13 groups and enrolled participants in 4 stages. The study used a stepwise age de-escalation and dose ascension design for children 6 months to less than (&lt;) 5 years of age.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Modified double-blind: the participant's parent / legally acceptable representative, the Investigator, and other study personnel remained unaware of the treatment assignments throughout the trial. An unblinded vaccine administrator administered the appropriate vaccine but was not involved in safety data collection.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Any Vaccination</measure>
    <time_frame>Within 30 minutes after any vaccination</time_frame>
    <description>An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious (SAEs) and non-serious unsolicited AEs. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. All participants were observed for 30 minutes after vaccination, and any unsolicited systemic AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events After Any Vaccination</measure>
    <time_frame>Within 28 days after any vaccination</time_frame>
    <description>An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both serious and non-serious unsolicited AEs. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Adverse reactions (ARs) were AEs related to vaccination. An injection site reaction was an AR at and around the injection site. Systemic AEs were all AEs that were not injection or administration site reactions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) After Any Vaccination</measure>
    <time_frame>From Day 0 up to 6 months (i.e. 180 days) post last vaccination</time_frame>
    <description>An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An SAE which caused death of the participant was considered as fatal SAE. Adverse events of special interest (AESIs) were defined as SAEs which included new onset of Guillain-Barré syndrome, encephalitis/myelitis (including transverse myelitis), Bell's palsy, convulsions, optic neuritis, and brachial neuritis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Achieving Seroconversion Against Antigens Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</measure>
    <time_frame>Day 28 post any vaccination</time_frame>
    <description>Anti-influenza antibodies were measured by hemagglutination inhibition (HAI) assay for strains A/H1N1, A/H3N2, B/Victoria and B/Yamagata lineage. Seroconversion: defined as either HAI titer &lt;10(1/dilution) at Day 0 and post-vaccination titer greater than or equal to (&gt;=)40(1/dilution) at Day 28, or HAI titer &gt;=10(1/dilution) at Day 0 and &gt;=4-fold increase in HAI titer (1/dilution) at Day 28. Data for this Outcome Measure (OM) was planned to be collected and reported for dose level (QIV-HD 30μg and 45μg) matched separate groups for QIV-SD (Groups 4a, 4b and 4c), instead of pooled QIV-SD arm. Due to complex study design and analysis of doses and age groups, QIV-SD group participants, who matched to participants in QIV-HD 30μg and 45μg dose formulations groups (who were 9 through 17 years old and shared matching age group with QIV-SD control group), included in Groups 4a, 4b and 4c in this OM might be counted in more than once in QIV-SD arms for different dose levels, as applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</measure>
    <time_frame>Day 28 post any vaccination</time_frame>
    <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Data for this OM was planned to be collected and reported for dose level (QIV-HD 30 μg and QIV-HD 45 μg) matched separate groups for QIV-SD (Groups 4a, 4b and 4c), instead of pooled QIV-SD arm. Due to the complex study design and analysis of the dose formulation and age groups in the study, QIV-SD group participants, who matched to participants in the QIV-HD 30 μg and QIV-HD 45 μg dose formulations groups (who were 9 through 17 years old and shared a matching age group with QIV-SD control group), included in Groups 4a, 4b and 4c in this OM might be counted in more than once in QIV-SD arms for different dose levels, as applicable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination), Day 28 (post any vaccination)</time_frame>
    <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. GMTRs were calculated as the ratio of GMTs post-vaccination and pre-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Neutralization Antibody Titers &gt;= 40 (1/Dilution) Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</measure>
    <time_frame>Day 28 post any vaccination</time_frame>
    <description>GMT was measured for each influenza strain using HAI assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers of Influenza Antibodies (Measured by Seroneutralization [SN] Assay) Following Vaccination With Either High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</measure>
    <time_frame>Day 28 post any vaccination</time_frame>
    <description>GMT was measured for each influenza strain using SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers Ratio of Influenza Antibodies (Measured by Seroneutralization Assay) Following Vaccination With Either High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</measure>
    <time_frame>Day 0 (pre-vaccination), Day 28 (post any vaccination)</time_frame>
    <description>GMTRs of anti-influenza antibodies were measured using SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage and B/Yamagata lineage. GMTRs were calculated as the ratio of GMTs post vaccination and pre-vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Neutralization Antibody Titers Above Pre-Defined Thresholds</measure>
    <time_frame>Day 28 post any vaccination</time_frame>
    <description>Neutralizing Antibody titer was measured for each influenza strain with SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage at pre-defined thresholds of &gt;=20, &gt;=40 and &gt;=80 (1/dilution).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Two-Fold and Four-Fold Increase in Neutralization Antibody Titer</measure>
    <time_frame>Day 28 post any vaccination</time_frame>
    <description>Neutralizing Antibody titer was measured for each influenza strain with SN method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage. 2-fold and 4-fold rise was defined as the computed value = post-vaccination computed value / pre-vaccination computed value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Injection Site Reactions</measure>
    <time_frame>Within 7 days after any vaccination</time_frame>
    <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited injection site reactions included tenderness/pain, erythema, swelling, induration and bruising.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic Reactions After Any Vaccination</measure>
    <time_frame>Within 7 days after any vaccination</time_frame>
    <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability. Fever was planned to be evaluated for the whole population where as, the other events (vomiting, crying abnormal, drowsiness, appetite lost, and irritability) were planned to be evaluated only in the participants aged 6 months to &lt;36 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic Reactions After Any Vaccination: Participants Aged &gt;36 Months</measure>
    <time_frame>Within 7 days after any vaccination</time_frame>
    <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited systemic reactions included: headache, malaise, myalgia and shivering.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">665</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Group 1: QIV-HD 30 μg (US: 6 months to 17 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from United States (US) (aged 6 months to 17 years) received single injection of 30 microgram (μg) QIV-HD, intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: QIV-HD 45 μg (US: 6 months to 17 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 months)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Canada (aged 6 to less than [&lt;] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 months)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)</intervention_name>
    <description>Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM</description>
    <arm_group_label>Group 1: QIV-HD 30 μg (US: 6 months to 17 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)</intervention_name>
    <description>Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM</description>
    <arm_group_label>Group 2: QIV-HD 45 μg (US: 6 months to 17 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)</intervention_name>
    <description>Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM</description>
    <arm_group_label>Group 3: QIV-HD, 60 μg (US: 6 months to 17 years)</arm_group_label>
    <arm_group_label>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 months)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: IM</description>
    <arm_group_label>Group 4: Pooled QIV-SD, 15 μg (US: 6 months to 17 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)</intervention_name>
    <description>Pharmaceutical form: Solution for injection Route of administration: IM</description>
    <arm_group_label>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 months)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Aged 6 months to 17 years on the day of inclusion.

          -  Assent form was signed and dated by the participant (7 to 17 years of age) and
             informed consent form was signed and dated by the parent(s) or guardian(s) and by an
             independent witness, if required by local regulations.

          -  Participant and parent/guardian were able to attend all scheduled visits and complied
             with all study procedures.

          -  For participants aged &lt;24 months: Born at full term of pregnancy (greater than or
             equal to [&gt;=] 37 weeks) and/or with a birth weight &gt;=2.5 kilogram.

        Exclusion criteria:

          -  Participant was pregnant, or lactating, or of childbearing potential and not using an
             effective method of contraception or abstinence from at least 4 weeks prior to
             vaccination until at least 4 weeks after vaccination. To be considered of
             non-childbearing potential, a female must be pre-menarche.

          -  Participation at the time of study enrollment (or in the 4 weeks preceding the first
             study vaccination) or planned participation during the present study period in another
             clinical study investigating a vaccine, drug, medical device, or medical procedure.

          -  Receipt of any vaccine in the 30 days preceding the first study vaccination, or
             planned receipt of any vaccine before Visit 3 for participants receiving 1 dose of
             influenza vaccine or Visit 5 for participants receiving 2 doses of influenza vaccine.

          -  For previously influenza vaccinated participants: Previous vaccination against
             influenza in the preceding 6 months with either the study vaccine or another vaccine.

          -  For previously influenza unvaccinated participants: Any influenza vaccination (from
             birth to the day of inclusion) with either the study vaccine or another influenza
             vaccine.

          -  For previously influenza unvaccinated participants: Any previous laboratory confirmed
             influenza infection (from birth to the day of inclusion)

          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months.

          -  Known or suspected congenital or acquired immunodeficiency; or receipt of
             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,
             within the preceding 6 months; or long-term systemic corticosteroid therapy
             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).

          -  Known systemic hypersensitivity to any of the vaccine components, or history of a
             life-threatening reaction to the vaccines used in the study or to a vaccine containing
             any of the same substances.

          -  Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on
             Investigator's judgement.

          -  Deprived of freedom by an administrative or court order, or in an emergency setting,
             or hospitalized involuntarily.

          -  Current alcohol abuse or drug addiction.

          -  Chronic illness that, in the opinion of the investigator, was at a stage where it
             might interfere with study conduct or completion.

          -  Moderate or severe acute illness/infection (according to investigator judgment) on the
             day of vaccination or febrile illness (temperature &gt;=38.0°Celsius
             [&gt;=100.4°Fahrenheit]). A prospective participant should not be included in the study
             until the condition had resolved or the febrile event had subsided.

          -  Identified as an immediate family member (i.e., spouse, natural or adopted child,
             grandchild, nephew, or niece) of the Investigator or employee with direct involvement
             in the proposed study.

          -  Personal history of Guillain-Barré syndrome.

          -  Any condition that in the opinion of the Investigator would pose a health risk to the
             participant if enrolled or could interfere with the evaluation of the vaccine

          -  Personal history of clinically significant development delay (at the discretion of the
             Investigator), neurologic disorder, or seizure disorder.

          -  Known seropositivity for hepatitis B or hepatitis C.

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 8400004</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123-1881</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400001</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400002</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400013</name>
      <address>
        <city>El Dorado</city>
        <state>Kansas</state>
        <zip>67042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400015</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400009</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400007</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400010</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400011</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400003</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400012</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400005</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 8400014</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088-8865</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1241003</name>
      <address>
        <city>Montreal</city>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1241002</name>
      <address>
        <city>Pierrefonds</city>
        <zip>H9H 4Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1241001</name>
      <address>
        <city>Quebec</city>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2018</study_first_posted>
  <results_first_submitted>May 14, 2020</results_first_submitted>
  <results_first_submitted_qc>May 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 1, 2020</results_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to participant level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Participant level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 25, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03698279/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 4, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT03698279/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 16 centers in United States (US) and Canada from 09 October 2018 to 16 October 2019.</recruitment_details>
      <pre_assignment_details>A total of 665 participants were enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 30 microgram (μg) high-dose quadrivalent influenza vaccine (QIV-HD), intramuscularly (IM) at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P2">
          <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P3">
          <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P4">
          <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
          <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted standard-dose quadrivalent influenza vaccine (QIV-SD), IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P5">
          <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
          <description>Participants from Canada (aged 6 to less than [&lt;] 24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="P6">
          <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
          <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted trivalent influenza vaccine (TIV), IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="122"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="234"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set Population (SafAS)</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="158"/>
                <participants group_id="P4" count="234"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="119"/>
                <participants group_id="P2" count="120"/>
                <participants group_id="P3" count="152"/>
                <participants group_id="P4" count="228"/>
                <participants group_id="P5" count="13"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by parent/guardian</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on the randomized participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B2">
          <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B3">
          <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B4">
          <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
          <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B5">
          <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
          <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B6">
          <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
          <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="122"/>
            <count group_id="B3" value="159"/>
            <count group_id="B4" value="234"/>
            <count group_id="B5" value="13"/>
            <count group_id="B6" value="13"/>
            <count group_id="B7" value="665"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.8" spread="3.91"/>
                    <measurement group_id="B2" value="6.1" spread="4.30"/>
                    <measurement group_id="B3" value="5.2" spread="4.22"/>
                    <measurement group_id="B4" value="5.1" spread="4.02"/>
                    <measurement group_id="B5" value="0.8" spread="0.19"/>
                    <measurement group_id="B6" value="1.0" spread="0.28"/>
                    <measurement group_id="B7" value="5.3" spread="4.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>6 - &lt; 24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - &lt; 36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months - &lt; 5 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - 8 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>9 - 17 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="114"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="318"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="120"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="157"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="458"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Any Vaccination</title>
        <description>An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious (SAEs) and non-serious unsolicited AEs. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. All participants were observed for 30 minutes after vaccination, and any unsolicited systemic AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.</description>
        <time_frame>Within 30 minutes after any vaccination</time_frame>
        <population>Analysis was performed on SafAS population which included participants who had received at least one dose of the study vaccines.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Immediate Unsolicited Adverse Events (AEs) After Any Vaccination</title>
          <description>An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs includes both serious (SAEs) and non-serious unsolicited AEs. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. All participants were observed for 30 minutes after vaccination, and any unsolicited systemic AEs occurred during that time were recorded as immediate unsolicited AEs in the CRB.</description>
          <population>Analysis was performed on SafAS population which included participants who had received at least one dose of the study vaccines.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Adverse Events After Any Vaccination</title>
        <description>An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both serious and non-serious unsolicited AEs. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Adverse reactions (ARs) were AEs related to vaccination. An injection site reaction was an AR at and around the injection site. Systemic AEs were all AEs that were not injection or administration site reactions.</description>
        <time_frame>Within 28 days after any vaccination</time_frame>
        <population>Analysis was performed on the SafAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events After Any Vaccination</title>
          <description>An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the CRB in terms of diagnosis and/or onset window post-vaccination. Unsolicited AEs included both serious and non-serious unsolicited AEs. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. Adverse reactions (ARs) were AEs related to vaccination. An injection site reaction was an AR at and around the injection site. Systemic AEs were all AEs that were not injection or administration site reactions.</description>
          <population>Analysis was performed on the SafAS population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="53"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited non-serious AR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited non-serious injection site AR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited non-serious systemic AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="45"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="80"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unsolicited non-serious systemic AR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs) After Any Vaccination</title>
        <description>An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An SAE which caused death of the participant was considered as fatal SAE. Adverse events of special interest (AESIs) were defined as SAEs which included new onset of Guillain-Barré syndrome, encephalitis/myelitis (including transverse myelitis), Bell's palsy, convulsions, optic neuritis, and brachial neuritis.</description>
        <time_frame>From Day 0 up to 6 months (i.e. 180 days) post last vaccination</time_frame>
        <population>Analysis was performed on the SafAS population.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs) After Any Vaccination</title>
          <description>An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. An SAE which caused death of the participant was considered as fatal SAE. Adverse events of special interest (AESIs) were defined as SAEs which included new onset of Guillain-Barré syndrome, encephalitis/myelitis (including transverse myelitis), Bell's palsy, convulsions, optic neuritis, and brachial neuritis.</description>
          <population>Analysis was performed on the SafAS population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Achieving Seroconversion Against Antigens Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
        <description>Anti-influenza antibodies were measured by hemagglutination inhibition (HAI) assay for strains A/H1N1, A/H3N2, B/Victoria and B/Yamagata lineage. Seroconversion: defined as either HAI titer &lt;10(1/dilution) at Day 0 and post-vaccination titer greater than or equal to (&gt;=)40(1/dilution) at Day 28, or HAI titer &gt;=10(1/dilution) at Day 0 and &gt;=4-fold increase in HAI titer (1/dilution) at Day 28. Data for this Outcome Measure (OM) was planned to be collected and reported for dose level (QIV-HD 30μg and 45μg) matched separate groups for QIV-SD (Groups 4a, 4b and 4c), instead of pooled QIV-SD arm. Due to complex study design and analysis of doses and age groups, QIV-SD group participants, who matched to participants in QIV-HD 30μg and 45μg dose formulations groups (who were 9 through 17 years old and shared matching age group with QIV-SD control group), included in Groups 4a, 4b and 4c in this OM might be counted in more than once in QIV-SD arms for different dose levels, as applicable.</description>
        <time_frame>Day 28 post any vaccination</time_frame>
        <population>Analysis was performed on immunogenicity analysis set (IAS) population which included randomized participants who received 1 dose or 2 doses of study vaccine and had a post-vaccination blood sample. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4a: QIV-SD, 15 μg, (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received 15 μg QIV-SD, IM and were restricted for comparison to relevant experimental study group QIV-HD 30 μg.</description>
          </group>
          <group group_id="O5">
            <title>Group 4b: QIV-SD, 15 μg, (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received 15 μg QIV-SD, IM and were restricted for comparison to relevant experimental study group QIV-HD 45 μg.</description>
          </group>
          <group group_id="O6">
            <title>Group 4c: QIV-SD, 15 μg, (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received 15 μg QIV-SD, IM and were restricted for comparison to relevant experimental study group QIV-HD 60 μg.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving Seroconversion Against Antigens Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
          <description>Anti-influenza antibodies were measured by hemagglutination inhibition (HAI) assay for strains A/H1N1, A/H3N2, B/Victoria and B/Yamagata lineage. Seroconversion: defined as either HAI titer &lt;10(1/dilution) at Day 0 and post-vaccination titer greater than or equal to (&gt;=)40(1/dilution) at Day 28, or HAI titer &gt;=10(1/dilution) at Day 0 and &gt;=4-fold increase in HAI titer (1/dilution) at Day 28. Data for this Outcome Measure (OM) was planned to be collected and reported for dose level (QIV-HD 30μg and 45μg) matched separate groups for QIV-SD (Groups 4a, 4b and 4c), instead of pooled QIV-SD arm. Due to complex study design and analysis of doses and age groups, QIV-SD group participants, who matched to participants in QIV-HD 30μg and 45μg dose formulations groups (who were 9 through 17 years old and shared matching age group with QIV-SD control group), included in Groups 4a, 4b and 4c in this OM might be counted in more than once in QIV-SD arms for different dose levels, as applicable.</description>
          <population>Analysis was performed on immunogenicity analysis set (IAS) population which included randomized participants who received 1 dose or 2 doses of study vaccine and had a post-vaccination blood sample. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="148"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="71"/>
                    <measurement group_id="O3" value="107"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="98"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="146"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="102"/>
                    <measurement group_id="O4" value="18"/>
                    <measurement group_id="O5" value="20"/>
                    <measurement group_id="O6" value="71"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="148"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="117"/>
                    <measurement group_id="O4" value="28"/>
                    <measurement group_id="O5" value="30"/>
                    <measurement group_id="O6" value="111"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="147"/>
                    <count group_id="O7" value="11"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="85"/>
                    <measurement group_id="O3" value="120"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="117"/>
                    <measurement group_id="O7" value="8"/>
                    <measurement group_id="O8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
        <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Data for this OM was planned to be collected and reported for dose level (QIV-HD 30 μg and QIV-HD 45 μg) matched separate groups for QIV-SD (Groups 4a, 4b and 4c), instead of pooled QIV-SD arm. Due to the complex study design and analysis of the dose formulation and age groups in the study, QIV-SD group participants, who matched to participants in the QIV-HD 30 μg and QIV-HD 45 μg dose formulations groups (who were 9 through 17 years old and shared a matching age group with QIV-SD control group), included in Groups 4a, 4b and 4c in this OM might be counted in more than once in QIV-SD arms for different dose levels, as applicable.</description>
        <time_frame>Day 28 post any vaccination</time_frame>
        <population>Analysis was performed on IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4a: QIV-SD, 15 μg, (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received 15 μg QIV-SD, IM and were restricted for comparison to relevant experimental study group QIV-HD 30 μg.</description>
          </group>
          <group group_id="O5">
            <title>Group 4b: QIV-SD, 15 μg, (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received 15 μg QIV-SD, IM and were restricted for comparison to relevant experimental study group QIV-HD 45 μg.</description>
          </group>
          <group group_id="O6">
            <title>Group 4c: QIV-SD, 15 μg, (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received 15 μg QIV-SD, IM and were restricted for comparison to relevant experimental study group QIV-HD 60 μg.</description>
          </group>
          <group group_id="O7">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O8">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
          <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. Data for this OM was planned to be collected and reported for dose level (QIV-HD 30 μg and QIV-HD 45 μg) matched separate groups for QIV-SD (Groups 4a, 4b and 4c), instead of pooled QIV-SD arm. Due to the complex study design and analysis of the dose formulation and age groups in the study, QIV-SD group participants, who matched to participants in the QIV-HD 30 μg and QIV-HD 45 μg dose formulations groups (who were 9 through 17 years old and shared a matching age group with QIV-SD control group), included in Groups 4a, 4b and 4c in this OM might be counted in more than once in QIV-SD arms for different dose levels, as applicable.</description>
          <population>Analysis was performed on IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="41"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="13"/>
                <count group_id="O8" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="151"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="673" lower_limit="525" upper_limit="863"/>
                    <measurement group_id="O2" value="676" lower_limit="524" upper_limit="873"/>
                    <measurement group_id="O3" value="834" lower_limit="674" upper_limit="1033"/>
                    <measurement group_id="O4" value="698" lower_limit="419" upper_limit="1161"/>
                    <measurement group_id="O5" value="791" lower_limit="480" upper_limit="1303"/>
                    <measurement group_id="O6" value="618" lower_limit="461" upper_limit="830"/>
                    <measurement group_id="O7" value="59.7" lower_limit="27.0" upper_limit="132"/>
                    <measurement group_id="O8" value="604" lower_limit="261" upper_limit="1398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="151"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="518" lower_limit="399" upper_limit="671"/>
                    <measurement group_id="O2" value="781" lower_limit="600" upper_limit="1017"/>
                    <measurement group_id="O3" value="770" lower_limit="604" upper_limit="982"/>
                    <measurement group_id="O4" value="314" lower_limit="184" upper_limit="538"/>
                    <measurement group_id="O5" value="441" lower_limit="264" upper_limit="738"/>
                    <measurement group_id="O6" value="307" lower_limit="239" upper_limit="395"/>
                    <measurement group_id="O7" value="66.4" lower_limit="33.0" upper_limit="133"/>
                    <measurement group_id="O8" value="604" lower_limit="386" upper_limit="946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="40"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="151"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="378" lower_limit="296" upper_limit="483"/>
                    <measurement group_id="O2" value="432" lower_limit="334" upper_limit="560"/>
                    <measurement group_id="O3" value="494" lower_limit="400" upper_limit="612"/>
                    <measurement group_id="O4" value="296" lower_limit="194" upper_limit="452"/>
                    <measurement group_id="O5" value="468" lower_limit="302" upper_limit="726"/>
                    <measurement group_id="O6" value="310" lower_limit="246" upper_limit="390"/>
                    <measurement group_id="O7" value="56.6" lower_limit="26.2" upper_limit="122"/>
                    <measurement group_id="O8" value="1244" lower_limit="767" upper_limit="2016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="39"/>
                    <count group_id="O5" value="41"/>
                    <count group_id="O6" value="151"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="723" lower_limit="582" upper_limit="899"/>
                    <measurement group_id="O2" value="720" lower_limit="556" upper_limit="932"/>
                    <measurement group_id="O3" value="877" lower_limit="722" upper_limit="1066"/>
                    <measurement group_id="O4" value="706" lower_limit="474" upper_limit="1050"/>
                    <measurement group_id="O5" value="727" lower_limit="501" upper_limit="1054"/>
                    <measurement group_id="O6" value="580" lower_limit="466" upper_limit="721"/>
                    <measurement group_id="O7" value="75.8" lower_limit="38.9" upper_limit="148"/>
                    <measurement group_id="O8" value="21.8" lower_limit="12.3" upper_limit="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
        <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. GMTRs were calculated as the ratio of GMTs post-vaccination and pre-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination), Day 28 (post any vaccination)</time_frame>
        <population>Analysis was performed on IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer Ratios (GMTRs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
          <description>GMTs of anti-influenza antibodies were measured using an HAI assay for 4 strains: A/H1N1, A/H3N2, B Victoria lineage, and B Yamagata lineage. GMTRs were calculated as the ratio of GMTs post-vaccination and pre-vaccination.</description>
          <population>Analysis was performed on IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="217"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.55" lower_limit="6.39" upper_limit="11.4"/>
                    <measurement group_id="O2" value="10.0" lower_limit="7.31" upper_limit="13.7"/>
                    <measurement group_id="O3" value="16.3" lower_limit="12.1" upper_limit="22.0"/>
                    <measurement group_id="O4" value="10.1" lower_limit="8.07" upper_limit="12.8"/>
                    <measurement group_id="O5" value="1.41" lower_limit="0.878" upper_limit="2.28"/>
                    <measurement group_id="O6" value="4.76" lower_limit="2.72" upper_limit="8.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="109"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="140"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" lower_limit="4.95" upper_limit="8.34"/>
                    <measurement group_id="O2" value="9.35" lower_limit="7.15" upper_limit="12.2"/>
                    <measurement group_id="O3" value="10.3" lower_limit="8.09" upper_limit="13.0"/>
                    <measurement group_id="O4" value="4.61" lower_limit="3.90" upper_limit="5.45"/>
                    <measurement group_id="O5" value="1.41" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O6" value="15.5" lower_limit="8.89" upper_limit="27.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="217"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="8.31" upper_limit="13.7"/>
                    <measurement group_id="O2" value="11.7" lower_limit="9.30" upper_limit="14.7"/>
                    <measurement group_id="O3" value="16.7" lower_limit="13.2" upper_limit="21.0"/>
                    <measurement group_id="O4" value="11.0" lower_limit="9.24" upper_limit="13.2"/>
                    <measurement group_id="O5" value="1.37" lower_limit="0.949" upper_limit="1.98"/>
                    <measurement group_id="O6" value="11.0" lower_limit="6.28" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="110"/>
                    <count group_id="O2" value="109"/>
                    <count group_id="O3" value="141"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28" lower_limit="7.10" upper_limit="12.1"/>
                    <measurement group_id="O2" value="11.4" lower_limit="8.83" upper_limit="14.7"/>
                    <measurement group_id="O3" value="18.1" lower_limit="13.9" upper_limit="23.6"/>
                    <measurement group_id="O4" value="9.77" lower_limit="8.15" upper_limit="11.7"/>
                    <measurement group_id="O5" value="1.71" lower_limit="1.07" upper_limit="2.73"/>
                    <measurement group_id="O6" value="0.944" lower_limit="0.785" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Neutralization Antibody Titers &gt;= 40 (1/Dilution) Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
        <description>GMT was measured for each influenza strain using HAI assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage.</description>
        <time_frame>Day 28 post any vaccination</time_frame>
        <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutralization Antibody Titers &gt;= 40 (1/Dilution) Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
          <description>GMT was measured for each influenza strain using HAI assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage.</description>
          <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="114"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="221"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="198"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="220"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="139"/>
                    <measurement group_id="O4" value="198"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria: Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="113"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="221"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="140"/>
                    <measurement group_id="O4" value="202"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata: Day 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="116"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="144"/>
                    <count group_id="O4" value="220"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="109"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="215"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers of Influenza Antibodies (Measured by Seroneutralization [SN] Assay) Following Vaccination With Either High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
        <description>GMT was measured for each influenza strain using SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage.</description>
        <time_frame>Day 28 post any vaccination</time_frame>
        <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers of Influenza Antibodies (Measured by Seroneutralization [SN] Assay) Following Vaccination With Either High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
          <description>GMT was measured for each influenza strain using SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage.</description>
          <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>titers (1/dilution)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6589" lower_limit="4959" upper_limit="8754"/>
                    <measurement group_id="O2" value="6213" lower_limit="4672" upper_limit="8264"/>
                    <measurement group_id="O3" value="7045" lower_limit="5514" upper_limit="9001"/>
                    <measurement group_id="O4" value="4948" lower_limit="3676" upper_limit="6659"/>
                    <measurement group_id="O5" value="33.8" lower_limit="14.8" upper_limit="76.9"/>
                    <measurement group_id="O6" value="234" lower_limit="32.0" upper_limit="1708"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="142"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="641" lower_limit="515" upper_limit="798"/>
                    <measurement group_id="O2" value="921" lower_limit="718" upper_limit="1181"/>
                    <measurement group_id="O3" value="884" lower_limit="717" upper_limit="1091"/>
                    <measurement group_id="O4" value="411" lower_limit="347" upper_limit="487"/>
                    <measurement group_id="O5" value="54.4" lower_limit="35.3" upper_limit="83.9"/>
                    <measurement group_id="O6" value="188" lower_limit="119" upper_limit="298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500" lower_limit="375" upper_limit="667"/>
                    <measurement group_id="O2" value="605" lower_limit="444" upper_limit="825"/>
                    <measurement group_id="O3" value="628" lower_limit="484" upper_limit="815"/>
                    <measurement group_id="O4" value="378" lower_limit="302" upper_limit="472"/>
                    <measurement group_id="O5" value="6.05" lower_limit="4.54" upper_limit="8.07"/>
                    <measurement group_id="O6" value="57.9" lower_limit="39.5" upper_limit="84.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="12"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1147" lower_limit="893" upper_limit="1474"/>
                    <measurement group_id="O2" value="1159" lower_limit="865" upper_limit="1552"/>
                    <measurement group_id="O3" value="1254" lower_limit="1015" upper_limit="1549"/>
                    <measurement group_id="O4" value="846" lower_limit="698" upper_limit="1026"/>
                    <measurement group_id="O5" value="17.6" lower_limit="11.1" upper_limit="27.8"/>
                    <measurement group_id="O6" value="17.4" lower_limit="9.86" upper_limit="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers Ratio of Influenza Antibodies (Measured by Seroneutralization Assay) Following Vaccination With Either High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
        <description>GMTRs of anti-influenza antibodies were measured using SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage and B/Yamagata lineage. GMTRs were calculated as the ratio of GMTs post vaccination and pre-vaccination.</description>
        <time_frame>Day 0 (pre-vaccination), Day 28 (post any vaccination)</time_frame>
        <population>Analysis was performed on IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers Ratio of Influenza Antibodies (Measured by Seroneutralization Assay) Following Vaccination With Either High-Dose Quadrivalent Influenza Vaccine or Standard-Dose Quadrivalent Influenza Vaccine or Adjuvanted Trivalent Influenza Vaccine</title>
          <description>GMTRs of anti-influenza antibodies were measured using SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage and B/Yamagata lineage. GMTRs were calculated as the ratio of GMTs post vaccination and pre-vaccination.</description>
          <population>Analysis was performed on IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="7.67" upper_limit="16.7"/>
                    <measurement group_id="O2" value="18.8" lower_limit="12.1" upper_limit="29.4"/>
                    <measurement group_id="O3" value="29.1" lower_limit="19.6" upper_limit="43.2"/>
                    <measurement group_id="O4" value="14.5" lower_limit="11.0" upper_limit="19.0"/>
                    <measurement group_id="O5" value="2.38" lower_limit="0.663" upper_limit="8.53"/>
                    <measurement group_id="O6" value="7.12" lower_limit="3.00" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="134"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.60" lower_limit="2.98" upper_limit="4.34"/>
                    <measurement group_id="O2" value="5.20" lower_limit="4.11" upper_limit="6.59"/>
                    <measurement group_id="O3" value="5.54" lower_limit="4.58" upper_limit="6.70"/>
                    <measurement group_id="O4" value="2.66" lower_limit="2.34" upper_limit="3.04"/>
                    <measurement group_id="O5" value="1.04" lower_limit="0.629" upper_limit="1.72"/>
                    <measurement group_id="O6" value="2.81" lower_limit="1.65" upper_limit="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="205"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="9.51" upper_limit="16.2"/>
                    <measurement group_id="O2" value="15.4" lower_limit="11.9" upper_limit="20.0"/>
                    <measurement group_id="O3" value="19.9" lower_limit="15.1" upper_limit="26.3"/>
                    <measurement group_id="O4" value="12.7" lower_limit="10.4" upper_limit="15.4"/>
                    <measurement group_id="O5" value="1.03" lower_limit="0.612" upper_limit="1.74"/>
                    <measurement group_id="O6" value="10.5" lower_limit="6.73" upper_limit="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata: Day 28/Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="204"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.75" lower_limit="7.50" upper_limit="12.7"/>
                    <measurement group_id="O2" value="11.5" lower_limit="9.06" upper_limit="14.7"/>
                    <measurement group_id="O3" value="14.1" lower_limit="11.1" upper_limit="17.8"/>
                    <measurement group_id="O4" value="8.49" lower_limit="7.18" upper_limit="10.0"/>
                    <measurement group_id="O5" value="1.16" lower_limit="0.604" upper_limit="2.24"/>
                    <measurement group_id="O6" value="1.10" lower_limit="0.760" upper_limit="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Neutralization Antibody Titers Above Pre-Defined Thresholds</title>
        <description>Neutralizing Antibody titer was measured for each influenza strain with SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage at pre-defined thresholds of &gt;=20, &gt;=40 and &gt;=80 (1/dilution).</description>
        <time_frame>Day 28 post any vaccination</time_frame>
        <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutralization Antibody Titers Above Pre-Defined Thresholds</title>
          <description>Neutralizing Antibody titer was measured for each influenza strain with SN assay method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage at pre-defined thresholds of &gt;=20, &gt;=40 and &gt;=80 (1/dilution).</description>
          <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1: &gt;=20 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="208"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: &gt;=40 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="147"/>
                    <measurement group_id="O4" value="202"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1: &gt;=80 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="201"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: &gt;=20 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="142"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="142"/>
                    <measurement group_id="O4" value="214"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: &gt;=40 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="142"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="111"/>
                    <measurement group_id="O3" value="141"/>
                    <measurement group_id="O4" value="208"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2: &gt;=80 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="111"/>
                    <count group_id="O3" value="142"/>
                    <count group_id="O4" value="215"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="138"/>
                    <measurement group_id="O4" value="190"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria: &gt;=20 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="143"/>
                    <measurement group_id="O4" value="201"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria: &gt;=40 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="104"/>
                    <measurement group_id="O3" value="136"/>
                    <measurement group_id="O4" value="195"/>
                    <measurement group_id="O5" value="8"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria: &gt;=80 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="113"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="216"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="128"/>
                    <measurement group_id="O4" value="181"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata: &gt;=20 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="112"/>
                    <measurement group_id="O3" value="146"/>
                    <measurement group_id="O4" value="213"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata: &gt;=40 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="145"/>
                    <measurement group_id="O4" value="208"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata: &gt;=80 (1/dilution)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="112"/>
                    <count group_id="O2" value="112"/>
                    <count group_id="O3" value="146"/>
                    <count group_id="O4" value="214"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="140"/>
                    <measurement group_id="O4" value="201"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Two-Fold and Four-Fold Increase in Neutralization Antibody Titer</title>
        <description>Neutralizing Antibody titer was measured for each influenza strain with SN method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage. 2-fold and 4-fold rise was defined as the computed value = post-vaccination computed value / pre-vaccination computed value.</description>
        <time_frame>Day 28 post any vaccination</time_frame>
        <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Two-Fold and Four-Fold Increase in Neutralization Antibody Titer</title>
          <description>Neutralizing Antibody titer was measured for each influenza strain with SN method for 4 strains: A/H1N1, A/H3N2, B/Victoria lineage, and B/Yamagata lineage. 2-fold and 4-fold rise was defined as the computed value = post-vaccination computed value / pre-vaccination computed value.</description>
          <population>Analysis was performed on the IAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
                <count group_id="O2" value="115"/>
                <count group_id="O3" value="156"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2-Fold Rise: A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="118"/>
                    <measurement group_id="O4" value="168"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold Rise: A/H1N1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="138"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="70"/>
                    <measurement group_id="O3" value="104"/>
                    <measurement group_id="O4" value="141"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Fold Rise: A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="134"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="110"/>
                    <measurement group_id="O4" value="111"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold Rise: A/H3N2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="134"/>
                    <count group_id="O4" value="206"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="72"/>
                    <measurement group_id="O4" value="61"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Fold Rise: B/Victoria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="205"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="99"/>
                    <measurement group_id="O3" value="131"/>
                    <measurement group_id="O4" value="185"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold Rise: B/Victoria</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="205"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="113"/>
                    <measurement group_id="O4" value="158"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2-Fold Rise: B/Yamagata</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="204"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="127"/>
                    <measurement group_id="O4" value="187"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-Fold Rise: B/Yamagata</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="101"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="137"/>
                    <count group_id="O4" value="204"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="81"/>
                    <measurement group_id="O3" value="109"/>
                    <measurement group_id="O4" value="142"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Injection Site Reactions</title>
        <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited injection site reactions included tenderness/pain, erythema, swelling, induration and bruising.</description>
        <time_frame>Within 7 days after any vaccination</time_frame>
        <population>Analysis was performed on the SafAS population. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Injection Site Reactions</title>
          <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited injection site reactions included tenderness/pain, erythema, swelling, induration and bruising.</description>
          <population>Analysis was performed on the SafAS population. Here, ‘overall number of participants analyzed’ = participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="119"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="232"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Injection site tenderness/pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="116"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="48"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Injection site bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic Reactions After Any Vaccination</title>
        <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability. Fever was planned to be evaluated for the whole population where as, the other events (vomiting, crying abnormal, drowsiness, appetite lost, and irritability) were planned to be evaluated only in the participants aged 6 months to &lt;36 months.</description>
        <time_frame>Within 7 days after any vaccination</time_frame>
        <population>Analysis was performed on the SafAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O5">
            <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O6">
            <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
            <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Reactions After Any Vaccination</title>
          <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited systemic reactions included fever, vomiting, crying abnormal, drowsiness, appetite loss and irritability. Fever was planned to be evaluated for the whole population where as, the other events (vomiting, crying abnormal, drowsiness, appetite lost, and irritability) were planned to be evaluated only in the participants aged 6 months to &lt;36 months.</description>
          <population>Analysis was performed on the SafAS population. Here, ‘number analyzed’ = number of participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="121"/>
                <count group_id="O3" value="158"/>
                <count group_id="O4" value="234"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="122"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="158"/>
                    <count group_id="O4" value="231"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Crying abnormal</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowsiness</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Appetite lost</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="54"/>
                    <count group_id="O4" value="74"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="23"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic Reactions After Any Vaccination: Participants Aged &gt;36 Months</title>
        <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited systemic reactions included: headache, malaise, myalgia and shivering.</description>
        <time_frame>Within 7 days after any vaccination</time_frame>
        <population>Analysis was performed on the SafAS population. Here, &quot;overall number of participants analyzed&quot;= participants evaluable for this outcome measure. Data not collected and reported for Groups 5 and 6 because none of the participants in both groups lies in the age group of &gt;36 months.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O2">
            <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O3">
            <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
            <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
          <group group_id="O4">
            <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
            <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Reactions After Any Vaccination: Participants Aged &gt;36 Months</title>
          <description>A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRB and considered as related to the administered vaccination. Solicited systemic reactions included: headache, malaise, myalgia and shivering.</description>
          <population>Analysis was performed on the SafAS population. Here, &quot;overall number of participants analyzed&quot;= participants evaluable for this outcome measure. Data not collected and reported for Groups 5 and 6 because none of the participants in both groups lies in the age group of &gt;36 months.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shivering</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from Day 0 (post-vaccination) up to 28 days after last vaccination. Solicited Reaction (SR) data were collected up to Day 7 after any vaccination. SAE data were collected throughout the study (up to 180 days after last vaccination).</time_frame>
      <desc>An SR was an AE that was prelisted (i.e., solicited) in the CRB and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the CRB in terms of diagnosis and/or onset window post-vaccination. Analysis was performed on SafAS population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1: QIV-HD 30 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 30 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E2">
          <title>Group 2: QIV-HD 45 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 45 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E3">
          <title>Group 3: QIV-HD, 60 μg (US: 6 Months to 17 Years)</title>
          <description>Participants from US (aged 6 months to 17 years) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E4">
          <title>Group 4: Pooled QIV-SD, 15 μg (US: 6 Months to 17 Years)</title>
          <description>Pooled arm consisted of participants who were from US aged 6 months to 17 years, randomized to Groups 1, 2 and 3 and received single injection of 15 μg unadjuvanted QIV-SD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E5">
          <title>Group 5: QIV-HD, 60 μg (Canada: 6 to &lt;24 Months)</title>
          <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 60 μg QIV-HD, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
        <group group_id="E6">
          <title>Group 6: Adjuvanted TIV (Canada: 6 to &lt;24 Months)</title>
          <description>Participants from Canada (aged 6 to &lt;24 months) received single injection of 7.5 μg adjuvanted TIV, IM at Day 0. Participants for whom 2 doses of influenza vaccine were recommended, a second dose was administered at Day 28.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA-22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA-22.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="122"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="121"/>
                <counts group_id="E3" subjects_affected="118" subjects_at_risk="158"/>
                <counts group_id="E4" subjects_affected="165" subjects_at_risk="234"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="121"/>
                <counts group_id="E3" events="10" subjects_affected="9" subjects_at_risk="158"/>
                <counts group_id="E4" events="13" subjects_affected="12" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="8" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral Mucosal Eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" events="16" subjects_affected="15" subjects_at_risk="234"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E6" events="9" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="122"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="121"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="158"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="234"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E6" events="10" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection Site Bruising</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="122"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="158"/>
                <counts group_id="E4" events="16" subjects_affected="16" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" events="32" subjects_affected="31" subjects_at_risk="122"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="121"/>
                <counts group_id="E3" events="44" subjects_affected="40" subjects_at_risk="158"/>
                <counts group_id="E4" events="52" subjects_affected="48" subjects_at_risk="234"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E6" events="9" subjects_affected="8" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="122"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="121"/>
                <counts group_id="E3" events="27" subjects_affected="26" subjects_at_risk="158"/>
                <counts group_id="E4" events="24" subjects_affected="22" subjects_at_risk="234"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="89" subjects_affected="81" subjects_at_risk="122"/>
                <counts group_id="E2" events="96" subjects_affected="84" subjects_at_risk="121"/>
                <counts group_id="E3" events="111" subjects_affected="100" subjects_at_risk="158"/>
                <counts group_id="E4" events="126" subjects_affected="116" subjects_at_risk="234"/>
                <counts group_id="E5" events="8" subjects_affected="6" subjects_at_risk="13"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection Site Swelling</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="121"/>
                <counts group_id="E3" events="35" subjects_affected="34" subjects_at_risk="158"/>
                <counts group_id="E4" events="25" subjects_affected="23" subjects_at_risk="234"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Injection Site Warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="122"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="121"/>
                <counts group_id="E3" events="27" subjects_affected="27" subjects_at_risk="158"/>
                <counts group_id="E4" events="33" subjects_affected="32" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="122"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E3" events="22" subjects_affected="19" subjects_at_risk="158"/>
                <counts group_id="E4" events="25" subjects_affected="24" subjects_at_risk="234"/>
                <counts group_id="E5" events="15" subjects_affected="9" subjects_at_risk="13"/>
                <counts group_id="E6" events="17" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="122"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="158"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="234"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E6" events="13" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="158"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tongue Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="122"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="121"/>
                <counts group_id="E3" events="18" subjects_affected="15" subjects_at_risk="158"/>
                <counts group_id="E4" events="24" subjects_affected="20" subjects_at_risk="234"/>
                <counts group_id="E5" events="14" subjects_affected="11" subjects_at_risk="13"/>
                <counts group_id="E6" events="14" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="122"/>
                <counts group_id="E2" events="31" subjects_affected="30" subjects_at_risk="121"/>
                <counts group_id="E3" events="34" subjects_affected="33" subjects_at_risk="158"/>
                <counts group_id="E4" events="45" subjects_affected="43" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="122"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="121"/>
                <counts group_id="E3" events="22" subjects_affected="22" subjects_at_risk="158"/>
                <counts group_id="E4" events="22" subjects_affected="22" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="122"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="121"/>
                <counts group_id="E3" events="17" subjects_affected="12" subjects_at_risk="158"/>
                <counts group_id="E4" events="21" subjects_affected="18" subjects_at_risk="234"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="122"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="121"/>
                <counts group_id="E3" events="24" subjects_affected="18" subjects_at_risk="158"/>
                <counts group_id="E4" events="27" subjects_affected="23" subjects_at_risk="234"/>
                <counts group_id="E5" events="11" subjects_affected="7" subjects_at_risk="13"/>
                <counts group_id="E6" events="19" subjects_affected="12" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sleep Terror</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="122"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="121"/>
                <counts group_id="E3" events="17" subjects_affected="15" subjects_at_risk="158"/>
                <counts group_id="E4" events="30" subjects_affected="30" subjects_at_risk="234"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="122"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="158"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="122"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="158"/>
                <counts group_id="E4" events="13" subjects_affected="13" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Diaper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="158"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="234"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="234"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="122"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="234"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable participant matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

